Trial Profile
Targeting Bruton's Tyrosine Kinase (BTK) With Ibrutinib After Autologous Stem Cell Transplantation in "Double-Hit" B-Cell Lymphoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications B-cell lymphoma
- Focus Therapeutic Use
- 03 Jan 2018 Status changed from active, no longer recruiting to discontinued due to slow accrual.
- 22 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2016 Status changed from not yet recruiting to recruiting.